BioCryst Pharmaceuticals (BCRX) CLO reports tax withholding and share sale

Rhea-AI Filing Summary

BioCryst Pharmaceuticals Chief Legal Officer Alane P. Barnes reported two equity transactions in December 2025. On December 12, 8,540 shares of common stock were withheld at $7.57 per share to satisfy required tax withholding tied to vesting restricted stock units, and this is explicitly described as not representing a sale by Barnes.

On December 15, Barnes sold 21,210 shares of common stock at $7.65 per share under a trading plan adopted on August 13, 2025 in accordance with Rule 10b5-1, with the transaction occurring automatically rather than as a discretionary trade. Following these transactions, Barnes directly beneficially owned 315,726 shares of BioCryst common stock.

Insider Trade Summary

Net Seller: 21,210 shares ($162,257)

Net Sell 2 txns

Insider Barnes Alane P

Role Chief Legal Officer

Sold 21,210 shs ($162K)

Type	Security	Shares	Price	Value
Sale	Common Stock	21,210	$7.65	$162K
Tax Withholding	Common Stock	8,540	$7.57	$65K

Holdings After Transaction: Common Stock — 315,726 shares (Direct)

Footnotes (1)

1. Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person. This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barnes Alane P

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		F		8,540(1)	D	$7.57	336,936	D
Common Stock	12/15/2025		S		21,210(2)	D	$7.65	315,726	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.

2. This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	/s/ Alane P. Barnes	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BioCryst Pharmaceuticals (BCRX) report for its Chief Legal Officer?

The Chief Legal Officer, Alane P. Barnes, reported two December 2025 transactions: 8,540 BioCryst common shares withheld to cover taxes on vesting restricted stock units and a separate sale of 21,210 shares of common stock.

How many BioCryst (BCRX) shares were sold and at what price?

On December 15, 2025, Alane P. Barnes sold 21,210 shares of BioCryst common stock at a price of $7.65 per share under a pre-established trading plan.

Were any of the BioCryst shares disposed of solely for tax withholding purposes?

Yes. On December 12, 2025, 8,540 BioCryst common shares at $7.57 per share were withheld by the issuer to satisfy required tax withholding obligations from vesting restricted stock units, and this is stated as not being a sale by the reporting person.

What is notable about the Rule 10b5-1 plan mentioned in the BioCryst (BCRX) filing?

The filing states that the sale of 21,210 shares was made under a plan adopted by Alane P. Barnes on August 13, 2025, in accordance with Rule 10b5-1, and the transaction occurred automatically and did not represent a discretionary decision by Barnes.

How many BioCryst Pharmaceuticals shares does the Chief Legal Officer own after these transactions?

After the reported December 2025 transactions, Alane P. Barnes directly beneficially owned 315,726 shares of BioCryst Pharmaceuticals common stock.

What is the reporting person’s role and relationship to BioCryst Pharmaceuticals (BCRX)?

The reporting person, Alane P. Barnes, is an officer of BioCryst Pharmaceuticals, serving as the company’s Chief Legal Officer, and files individually as one reporting person.